SCHEMBL20140064

SCHEMBL20140064

C=Cc1cc(C(=O)O)c(F)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
ASPH Q12797 1/20 0.40
KDM8 Q8N371 1/20 0.40
KEAP1 Q14145 2/20 0.36
NFE2L2 Q16236 1/20 0.36
ALB P02768 2/20 0.34
AKR1C2 P52895 2/20 0.33
AKR1C1 Q04828 2/20 0.33
MIF P14174 1/20 0.33
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
SLC22A6 Q4U2R8 2/20 0.32
SLC22A8 Q8TCC7 1/20 0.32
CYP3A4 P08684 1/20 0.31
ACMSD Q8TDX5 2/20 0.31
SLC22A12 Q96S37 1/20 0.31
AKR1C4 P17516 1/20 0.31
AKR1C3 P42330 1/20 0.31
ERN1 O75460 1/20 0.31
RARB P10826 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17262516 0.83 SLC22A6 (0.38) KDM4EASPHKDM8KEAP1NFE2L2
SCHEMBL20140332 0.82 ERN1 (0.44) KDM4EASPHKDM8KEAP1NFE2L2
SCHEMBL5309800 0.79 GLRA3 (0.36) KDM4EASPHKDM8KEAP1NFE2L2
SCHEMBL28739972 0.78 SLC22A6 (0.43) KDM4EAKR1C2AKR1C1SLC22A6SLC22A8
SCHEMBL28921318 0.78 ASPH (0.40) KDM4EASPHKDM8KEAP1NFE2L2
SCHEMBL20156870 0.78 CA12 (0.36) KDM4EERN1ALDH1A1CA1CA2
SCHEMBL5872835 0.78 KDM4E (0.52) KDM4EASPHKDM8KEAP1NFE2L2
SCHEMBL1563264 0.76 KEAP1 (0.33) KDM4EASPHKDM8KEAP1NFE2L2
SCHEMBL31258575 0.75 KEAP1 (0.50) KDM4EASPHKDM8KEAP1NFE2L2
SCHEMBL363928 0.75 KEAP1 (0.50) KDM4EASPHKDM8KEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4725941-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-04-15 EP disclosed
CN-115803024-B Compositions comprising aryl amide derivatives 中外制药株式会社 2025-01-10 CN disclosed
CN-114929669-B Aryl amide derivatives with antitumor activity 中外制药株式会社 2024-11-29 CN disclosed
US-20240327355-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-10-03 US disclosed
US-20240246922-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-07-25 US disclosed
EP-4375273-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-29 EP disclosed
US-11964950-B2 Arylamide derivative having antitumor activity CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-04-23 US disclosed
CN-117677607-A Process for producing aryl amide derivative 中外制药株式会社 2024-03-08 CN disclosed
US-20230270730-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-08-31 US disclosed
EP-4186506-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-31 EP disclosed
CN-115803024-A Composition comprising arylamide derivatives 中外制药株式会社 2023-03-14 CN disclosed
WO-2023003014-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE 中外製薬株式会社 2023-01-26 WO disclosed
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-05 US disclosed
CN-114929669-A Arylamide derivatives having antitumor activity 中外制药株式会社 2022-08-19 CN disclosed
WO-2022018875-A1 ARYLAMIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CELL PROLIFERATION DISEASES 中外製薬株式会社 2022-01-27 WO disclosed
WO-2021149776-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY 中外製薬株式会社 2021-07-29 WO disclosed
WO-2018089433-A1 PHENYL mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230270730-A1 COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE BRAF, NRAS, KRAS KDM4E 597/4885ASPH 2545/4885KDM8 802/4885
US-20240246922-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY BRAF, RAF1, NRAS KDM4E 1751/4885ASPH 3615/4885KDM8 1725/4885
US-11964950-B2 Arylamide derivative having antitumor activity BRAF, NRAS, KRAS KDM4E 1541/4885ASPH 3671/4885KDM8 1427/4885
US-20240327355-A1 METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE BRAF, RAF1, NRAS KDM4E 205/4885ASPH 1932/4885KDM8 197/4885
US-20230002333-A1 ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY BRAF, NRAS, KRAS KDM4E 1507/4885ASPH 3738/4885KDM8 1391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.